

NEVRO CORP

Form S-8

February 21, 2019

As filed with the Securities and Exchange Commission on February 21, 2019

Registration No. 333-

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM S-8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

NEVRO CORP.

(Exact name of registrant as specified in its charter)

Delaware  
(State or other jurisdiction of  
incorporation or organization) 56-2568057  
(IRS Employer  
Identification No.)

1800 Bridge Parkway

Redwood City, CA 94065

(Address of Principal Executive Offices) (Zip Code)

2014 Equity Incentive Award Plan

2014 Employee Stock Purchase Plan

(Full title of the plan)

Rami Elghandour

Chief Executive Officer

Nevro Corp.

1800 Bridge Parkway

Redwood City, CA 94065

(Name and address of agent for service)

(650) 251-0005

(Telephone number, including area code, of agent for service)

Edgar Filing: NEVRO CORP - Form S-8

Copies to:

Brian J. Cuneo, Esq.      Kashif Rashid, Esq.

Latham & Watkins LLP      General Counsel

140 Scott Drive      Nevro Corp.

Menlo Park, CA 94025      1800 Bridge Parkway

(650) 328-4600      Redwood City, CA 94065

(650) 251-0005

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer      Accelerated filer

Non-accelerated filer      Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.

CALCULATION OF REGISTRATION FEE

Title of Securities	Amount	Proposed Maximum	Proposed Maximum	Amount of Registration Fee
To Be Registered Common Stock, \$0.001 par value	Registered (1) 1,210,541 (2)	Per Share \$ 48.13 (3)	Offering Price \$58,263,338.33	\$7,061.51

Edgar Filing: NEVRO CORP - Form S-8

Common Stock, \$0.001 par value	302,635 (4)	\$ 48.13 (3)	\$14,565,822.55	\$1,765.38
Total:	1,513,176		\$72,829,160.88	\$8,826.89

(1) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this registration statement shall also cover any additional shares of the common stock of Nevro Corp. (the “Registrant”) that become issuable under the 2014 Equity Incentive Award Plan (the “2014 Plan”) and the 2014 Employee Stock Purchase Plan (the “ESPP”), by reason of any stock dividend, stock split, recapitalization or similar transaction effected without the Registrant’s receipt of consideration which would increase the number of outstanding shares of common stock.

(2) Represents the additional shares of common stock available for future issuance under the 2014 Plan resulting from an annual increase as of January 1, 2019.

(3) This estimate is made pursuant to Rule 457(c) and Rule 457(h) of the Securities Act solely for purposes of calculating the registration fee. The Proposed Maximum Offering Price Per Share for shares available for future grant is the average of the high and low prices for the registrant’s common stock as reported on The New York Stock Exchange on February 19, 2019, which is \$48.13.

(4) Represents the additional shares of common stock available for future issuance under the ESPP resulting from an annual increase as of January 1, 2019.

Proposed sale to take place as soon after the effective date of the

registration statement as awards under the plans are granted, exercised and/or vest.

## EXPLANATORY NOTE

This Registration Statement on Form S-8 is being filed for the purpose of registering an additional 1,513,176 shares of the Registrant's common stock issuable under the following employee benefit plans for which Registration Statements of the Registrant on Form S-8 (File Nos. 333-200145, 333-202857, 333-209816, 333-216206 and 333-223159) is effective: (i) the 2014 Equity Incentive Award Plan, as a result of the operation of an automatic annual increase provision therein, which added 1,210,541 shares of common stock, and (ii) the 2014 Employee Stock Purchase Plan, as a result of the operation of an automatic annual increase provision therein, which added 302,635 shares of common stock.

## INCORPORATION BY REFERENCE OF CONTENTS OF REGISTRATION STATEMENTS ON

## FORM S-8

Pursuant to Instruction E of Form S-8, the contents of the Registration Statements on Form S-8 filed with the Securities and Exchange Commission (File Nos. 333-200145, 333-202857, 333-209816, 333-216206 and 333-223159) are incorporated by reference herein.

## EXHIBIT INDEX

Exhibit Number	Description of Document	Incorporated by Reference			Filed Herewith
		Form	Date	Number	
4.1	<u>Amended and Restated Certificate of Incorporation.</u>	8-K	11/12/2014	3.1	
4.2	<u>Amended and Restated Bylaws.</u>	8-K	11/12/2014	3.2	
4.3	<u>Form of Common Stock Certificate.</u>	S-1/A	10/27/2014	4.2	
5.1	<u>Opinion of Latham &amp; Watkins LLP.</u>				X
23.1	<u>Consent of Independent Registered Public Accounting Firm.</u>				X
23.2	<u>Consent of Latham &amp; Watkins LLP (included in Exhibit 5.1).</u>				X
24.1	<u>Power of Attorney. Reference is made to the signature page to the Registration Statement.</u>				X
99.1(a)#	<u>Nevro Corp. 2014 Equity Incentive Award Plan.</u>	S-8	11/12/2014	99.2(a)	
99.1(b)#	<u>Form of Stock Option Grant Notice and Stock Option Agreement under the 2014 Equity Incentive Award Plan.</u>	S-1/A	10/10/2014	10.9(b)	
99.1(c)#	<u>Form of Restricted Stock Award Agreement and Restricted Stock Award Grant Notice under the 2014 Equity Incentive Award Plan.</u>	S-1/A	10/10/2014	10.9(c)	

Edgar Filing: NEVRO CORP - Form S-8

99.1(d)#	<u>Form of Restricted Stock Unit Award Agreement and Restricted Stock Unit Award Grant Notice under the 2014 Equity Incentive Award Plan.</u>	S-1/A	10/10/2014	10.9(d)
99.2#	<u>Nevro Corp. 2014 Employee Stock Purchase Plan.</u>	S-8	11/12/2014	99.3

#Indicates management contract or compensatory plan.

---

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Redwood City, State of California, on this 21st day of February, 2019.

NEVRO CORP.

By: /s/ RAMI ELGHANDOUR  
 Name: Rami Elghandour  
 Title: Chief Executive Officer

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each individual whose signature appears below constitutes and appoints Rami Elghandour and Andrew H. Galligan, and each of them, as attorneys-in-fact, each with the power of substitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto and all documents in connection therewith, with the Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that such attorneys-in-fact and agents or any of them, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

Signature	Title	Date
/s/ RAMI ELGHANDOUR Rami Elghandour	President and Chief Executive Officer (Principal Executive Officer)	February 21, 2019
/s/ ANDREW H. GALLIGAN Andrew H. Galligan	Chief Financial Officer (Principal Financial and Accounting Officer)	February 21, 2019
/s/ MICHAEL DEMANE Michael DeMane	Chairman of the Board	February 21, 2019
/s/ ALI BEHBAHANI Ali Behbahani, M.D.	Director	February 21, 2019

Edgar Filing: NEVRO CORP - Form S-8

/s/ FRANK FISCHER	Director	February 21, 2019
Frank Fischer		
/s/ WILFRED E. JAEGER	Director	February 21, 2019
Wilfred E. Jaeger, M.D.		
/s/ SHAWN T MCCORMICK	Director	February 21, 2019
Shawn T McCormick		
/s/ LISA EARNHARDT	Director	February 21, 2019
Lisa Earnhardt		
/s/ BRAD H. VALE	Director	February 21, 2019
Brad H. Vale, Ph.D., D.V.M.		